SELECT · 2023

SELECT — Semaglutide and cardiovascular outcomes

Cardiovascular outcomes in non-diabetic adults with established CVD.

Headline finding

20% reduction in MACE vs placebo.

Population
17,604 adults with established CVD, BMI ≥27, no diabetes
Duration
208 weeks
Citation
Lincoff AM et al., NEJM 2023

Summary is editorial; consult the original publication for the full methodology and statistical detail.

Get matched

Want a real recommendation?

Five minutes. Free. No pressure.

Start my consultation